The global polycystic ovary syndrome (PCOS) supplements market—valued at USD 1.17 billion in 2024 and projected to grow at a CAGR of 14.13% through 2034—is witnessing pronounced regional divergence shaped by healthcare accessibility, regulatory frameworks, and cultural attitudes toward hormonal health. North America dominates the market, accounting for nearly 45% of global revenue,...